We treated HCC cells with PGD2, a direct substrate of AKR1C3, and showed that exogenous PGD2 increased neither cell viability nor the number of LDs upon treatment with sorafenib in the parental HCC cells (Figure S5A-D). This evidence concerns the gene AKR1C3 and hepatocellular carcinoma.